EADV 2025｜化脓性汗腺炎研究进展

在2025年EADV大会上，挪威的Thrasyvoulos Tzellos 教授分享了化脓性汗腺炎（HS）治疗领域令人振奋的新进展。 Thrasyvoulos Tzellos 教授指出，HS是一种与银屑病类似的慢性炎症性皮肤疾病，以化脓性病变、引流窦道、剧烈疼痛及生活质量严重下降为特征，对患者造成沉重负担。 本次大会公布了靶向IL-17通路药物（如比奇珠单抗和司库奇尤单抗）的重要里程碑数据。这些药物显示出对闭合引流窦道、减轻疼痛、改善生活质量和降低炎症的显著疗效，并积累了长达三年的持久疗效与安全性证据。 展望未来，教授介绍了即将在未来几年上市的新疗法，包括靶向JAK抑制剂（如乌帕替尼、Povorcitinib）及靶向IL-1的药物（如Lutikizumab）。他强调，最值得期待的是联合治疗策略，即同时针对疾病不同通路进行治疗，甚至有望对抗HS中的纤维化进程。 Thrasyvoulos Tzellos 教授总结道，化脓性汗腺炎的治疗前景一片光明。他鼓励全球同仁通过EADV平台加强合作与交流，共同推动该领域的发展。  

At the EADV 2025 congress, Professor Thrasyvoulos Tzellos from Nordland University Hospital in Norway shared exciting news regarding Hidradenitis Suppurativa (HS). Professor Thrasyvoulos Tzellos highlighted that HS is a chronic inflammatory skin disease, similar to psoriasis, which is debilitating for patients. It is characterized by suppurative lesions, draining tunnels, pain, and a significantly reduced quality of life. The congress featured important milestone data for agents targeting the IL-17 pathway, namely Bimekizumab and Secukinumab. These agents have demonstrated effects on draining tunnels, reduction in pain, improved quality of life, and lower inflammation. Data supporting their efficacy and safety now extend up to three years. Looking ahead, the professor discussed upcoming treatments expected to reach the market in the next few years. These include therapies targeting Janus Kinase inhibition, such as Upadacitinib and Povorcitinib, as well as IL-1 targeted treatments like Lutikizumab. Most importantly, he emphasized the future potential of combination treatments targeting different disease pathways simultaneously, which also hold promise for combating fibrosis. In conclusion, Professor Thrasyvoulos  Tzellos expressed that the future for Hidradenitis Suppurativa is bright and full of exciting news. He warmly encouraged colleagues from China and all over the world to connect through the EADV network and publish in its journal to foster collaboration and advance the field together.